Robert Lancaster
Family · Cedar Rapids, IANPI 1811409006
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 385 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,712, 2.3 times the $735 reported in 2021. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$875
- Pfizer$835
- AbbVie$834
- Amgen$497
- Novo Nordisk$461
- Boehringer Ingelheim$272
- plus $2K from 34 others
What the payments were for
- Food & beverage$6,153100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $875 |
| Pfizer | 58 | $835 |
| AbbVie | 53 | $834 |
| Amgen | 45 | $497 |
| Novo Nordisk | 29 | $461 |
| Boehringer Ingelheim | 16 | $272 |
| Lilly USA, LLC | 17 | $261 |
| Abbott | 13 | $256 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $247 |
| Johnson & Johnson | 9 | $169 |
| Astellas Pharma US Inc | 7 | $165 |
| GSK | 11 | $161 |
| Biohaven Pharmaceuticals, Inc. | 7 | $112 |
| Phathom Pharmaceuticals, Inc. | 3 | $90 |
| Merck | 5 | $83 |
| Novartis | 4 | $73 |
| Bayer | 4 | $68 |
| Esperion Therapeutics, Inc. | 4 | $59 |
| Lundbeck LLC | 2 | $53 |
| Dynavax Technologies Corporation | 3 | $52 |
| Insulet Corporation | 1 | $45 |
| Dexcom, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Vertex | 2 | $33 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Coopersurgical, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $19 |
| Exact Sciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Modernatx, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,173 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 73 | $76,714 |
| OzempicSemaglutide | 34 | $59,984 |
| XareltoRivaroxaban | 29 | $39,659 |
| TrulicityDulaglutide | 11 | $14,185 |
| TradjentaLinagliptin | 17 | $12,507 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $10,489 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $7,793 |
| Varenicline Tartrate | 26 | $5,623 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,502 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $4,610 |
| DuleraMometasone/Formoterol | 11 | $4,273 |
| Atorvastatin Calcium | 560 | $3,687 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 33 | $2,306 |
| Gabapentin | 134 | $2,033 |
| Pregabalin | 20 | $1,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $272 | $89,22090 claims |
| Novo NordiskOzempic | $461 | $59,98434 claims |
| Johnson & JohnsonXarelto | $169 | $39,65929 claims |
| Lilly USA, LLCTrulicity | $261 | $14,18511 claims |
| GSKAnoro Ellipta | $161 | $5,50211 claims |
| MerckDulera | $83 | $4,27311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Cedar Rapids
- Kristen BellCedar Rapids$9K
- Sara ButlerCedar Rapids$6K
- Frankie DunbarCedar Rapids$4K
- Nicole SporrerCedar Rapids$4K
- Amy GanskeCedar Rapids$3K
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.